Use of trifunctional bispecific and trispecific antibodies for the treatment of malignant ascites
AssigneeTrion Pharma GmbH
InventorHorst Lindhofer
Life of this patent
Estimating the term…
Abstract
The invention describes the use of a pharmaceutical preparation containing a trifunctional bispecific and/or trispecific having the following properties: a) binding to a T cell; b) binding to at least an antigen on a tumor cell associated with malignant ascites and/or pleural effusion; c) binding, by its Fc portion (in the case of bispecific antibodies) or by a third specificity (in the case of trispecific antibodies), to Fc receptor-positive cells for the destruction of the tumor cells in the treatment of malignant ascites and/or pleural effusion.
Claims24
A method for inhibiting or reducing the formation of malignant ascites, pleural effusion, or a combination thereof in a subject, the method comprising administering to a subject having malignant ascites and/or pleural effusion one or more doses of a pharmaceutical preparation comprising a trifunctional bispecific and/or trispecific antibody, wherein the trifunctional bispecific and/or the trispecific antibody comprises:
- a) a first binding arm that binds to a T cell in the subject;
- b) a second binding arm that binds to an antigen on a tumor cell associated with malignant ascites or pleural effusion in the subject;
- and;
- c) an Fc portion that binds to an Fc receptor-positive cell in the subject,
- thereby destroying the tumor cell and treating the malignant ascites, the pleural effusion, or the combination thereof in the subject.
Dependencies are inferred from the claim text.